Type and hit ENTER

ProAxsis specialises in four key areas of business:

NEATstik®
Neutrophil Elastase Airways Test
  • Rapid point-of-care tests – NEATstik®, a lateral flow test for measuring active neutrophil elastase at point-of-care, was registered with a CE Mark in September 2017.
Clinical research services
Academic and Pharmaceutical Company Researchers
  • Our experienced team can provide a number of services for both academic and pharmaceutical company researchers, and are able to offer sample analysis at our purpose-built laboratory for a range of proteases and other inflammatory biomarkers.
ProAxsis R&D Projects
are supported by a variety of external partners
  • ProAxsis has a number of R&D projects ongoing, whch are supported by a variety of external partners. We are also able to conduct bespoke R&D projects at the request of academic groups or pharmaceutical companies.

NEWS

ProAxsis was delighted to support the recent School of Pharmacy Undergraduate Awards at Queen’s University, Belfast.  For the second year running, the company sponsored the award for Distinction in Industrial Pharmaceutics. This year, the prize was awarded to Zara-Louise Farmer, who is pictured above receiving her award from …

October 25, 2019

ProAxsis is pleased to confirm that Professor Stephen Smith has become the Chairman of the company’s Board of Directors with immediate effect. Stephen has held senior leadership roles in the NHS and academia, including with the University of Cambridge, Imperial College, London and Imperial College Healthcare NHS …

October 25, 2019

Positive early data from the BRIDGE1 study, a three-year 1000+ patient study in bronchiectasis funded by the British Lung Foundation (BLF) and the European Respiratory Society (ERS), has been published in the latest edition of the European Respiratory Journal2 and demonstrates the potential for NEATstik®, a point-of-care …

June 3, 2019
GET CONNECTED
RECENT POSTS
ABOUT US
TECHNOLOGY
SERVICES
ProAxsis | developing products for the capture, detection and measurement of active protease biomarkers of disease